UBS analyst David Lai initiated coverage of Immunocore (IMCR) with a Sell rating and $24 price target The firm launched coverage of SMID cap biotech sector with a focus in oncology and autoimmune diseases. Its top pick is Syndax. The analyst says moderate Kimmtrak growth and looming competition will likely to put shares of Immunocore under pressure.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMCR:
- Immunocore price target lowered to $74 from $80 at Morgan Stanley
- Immunocore downgraded to Neutral from Buy at Guggenheim
- Immunocore downgraded at Guggenheim with trajectory for Kimmtrak appreciated
- Immunocore presents Phase 1 data of brenetafusp in ovarian cancer
- Immunocore CFO Brian Di Donato to depart